[1] World Health Organization. Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection: Mar-15. WHO, 2015.
[2] 张国民, 缪宁, 郑徽, 等. 中国 2005—2016 年乙型病毒性肝炎报告发病的年龄和地区特征. 中国疫苗和免疫, 2018, 24: 121-126.
[3] Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016, 1: 196-206.
[4] 吴丽君. 对临床检测HBV DNA筛查隐匿性HBV携带者的探讨. 中外医学研究, 2015, 13: 62-63.
[5] 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2010年版). 中华内科杂志, 2011, 3: 1-12.
[6] Shainer R, Almogi-Hazan O, Berger A, et al. PreImplantation factor (PIF) therapy provides comprehensive protection against radiation induced pathologies. Onco target, 2016, 7: 58975.
[7] Fu X, Tan D, Dou X, et al. A multi-center clinical study comparing Sansure Magb and CAP/CTM HBV tests in the quantitative detection of HBV DNA. J Infect Dev Countr, 2016, 10: 755-761.
[8] Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016, 63: 261-283.
[9] 孙敏, 陈巧真, 赵华菊, 等. HBV慢性感染者PC/BCP区变异特点及血清检测指标临床意义. 中国热带医学, 2017, 17: 912-914.
[10] 廖宝林, 林思炜, 陈伟烈, 等. HBV前C/C基因启动子区变异与HBeAg阴性CHB患者肝组织病理变化的关系. 实用医学杂志, 2016, 32: 2347-2350.
[11] Yamani LN, Yano Y, Utsumi T, et al. Profile of mutations in the reverse transcriptase and overlapping surface genes of hepatitis B virus (HBV) in treatment-naïve indonesian HBV carriers. Jpn J Infect Dis, 2017, 70: 647-655.
[12] Lelie N, Bruhn R, Busch M, et al. Detection of different categories of hepatitis B virus (HBV) infection in a multi‐regional study comparing the clinical sensitivity of hepatitis B surface antien and HBV DNA testing. Transfusion, 2017, 57: 24-35.
[13] Huang JT, Yang Y, Hu YM, et al. A highly sensitive and robust method for hepatitis B virus covalently closed circular DNA detection in single cells and serum. J Mol Diagn, 2018, 20: 334-343.
[14] Shinkai N, Kusumoto S, Murakami S, et al. Novel monitoring of hepatitis B reactivation based on ultra‐high sensitive hepatitis B surface antigen assay. Liver Int, 2017, 37: 1138-1147.
[15] Minekawa T, Takehara S, Takahashi M, et al. Development of a highly sensitive bioluminescent enzyme immunoassay for hepatitis B virus surface antigen capable of detecting divergent mutants. Clin Diagn Lab Immunol NLM, 2013, 20: 1255-1265.
[16] Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016, 1: 196-206.
[17] 陈金荣. 替诺福韦酯联合拉米夫定治疗艾滋病合并乙型肝炎病毒感染的临床疗效. 临床合理用药杂志, 2017, 10: 21-22.
[18] Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Digest dis sci, 2015, 60: 1457-1464. |
